Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis-Reference-Cited by-同舟云学术

Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis

Published:2022-12 Issue: Volume:68 Page:104220
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Tedeholm H,Piehl F,Lycke J,Link J,Stawiarz L,Burman J,de Flon P,Fink K,Gunnarsson M,Mellergård J,Nilsson P,Sundström P,Svenningsson A,Johansson H,Andersen O^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference31 articles.

1. Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics;Albertsson-Wikland;J. Clin. Endocrinol. Metab.,2016

2. Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden;Beiki;JAMA Neurol.,2019

3. Immunomodulatory therapies delay disease progression in multiple sclerosis;Bergamaschi;Mult. Scler.,2016

4. Statistical methods in cancer research. Volume II–The design and analysis of cohort studies;Breslow;IARC Sci. Publ.,1987

5. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis;Brown;JAMA,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis;Neurobiology of Disease;2024-10

2. Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis;Patient Preference and Adherence;2024-02

3. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China;Therapeutic Advances in Neurological Disorders;2024-01

4. Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population;Advances in Clinical Neuroscience & Rehabilitation;2024

5. Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS;Multiple Sclerosis Journal;2023-10-03